Nephropathy
Conditions
Brief summary
To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
Detailed description
Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
Interventions
DRUGParicalcitol
Sponsors
Jaume Arnó Renal Foundation
Effice Servicios Para la Investigacion S.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged between 50 and 75 years. * Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD). * Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml. * Plasma concentrations of 25 (OH) vitamin D \<30 ng/ml. * Without vitamin D supplementation for 3 months before the study. * Serum P\> 3.8 mg / dl. * Serum Ca\> 9.8 mg / dl. * No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease). * No
Exclusion criteria
for the use of contrast.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevention on vessels progression based on paricalcitol intake. | participants will be followed for the duration of whole study, an expected average of 1 year | Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification. |
Outcome results
None listed